GLP-1 Collective

Policy Tracker · Patient Lens · July 13, 2026

Seven new lawsuits accuse Novo Nordisk and Lilly of the same pricing story

Each patient filed alone, but the complaints all point to one question courts now have to answer about how these drugs get priced.

7 developments affecting GLP-1 access were tracked on Sunday, July 12, 2026, across 1 category. Each entry links to the full record.

## Courts and enforcement

**[Novo Nordisk faces lawsuit over Ozempic and Wegovy pricing](/lawsuits/cl-73609850)**.

**[Colozzi sues Novo Nordisk over pricing and marketing](/lawsuits/cl-73609587)**.

**[Ingram sues Eli Lilly over GLP-1 marketing practices](/lawsuits/cl-73608743)**.

**[Patient sues Eli Lilly over Mounjaro or Zepbound](/lawsuits/cl-73608309)**.

**[Lawsuit targets Novo Nordisk's Ozempic and Wegovy pricing](/lawsuits/cl-73607290)**.

**[Harmon v. Novo Nordisk: pricing lawsuit still in court](/lawsuits/cl-73606467)**.

**[Novo Nordisk sued over pricing and marketing of Ozempic, Wegovy](/lawsuits/cl-73610182)**.

By Amanda Bonello

Originally published by Patient Lens on GLP-1 Laws, operated by GLP-1 Studio LLC — a for-profit company founded by the Collective's Executive Director. Republished here in full, with permission, at no cost. The Collective pays nothing for it and receives no payment for publishing it. How this works.